Wright, DavidRolnik, Daniel LSyngelaki, Argyrode Paco Matallana, CatalinaMachuca, Miriande Alvarado, MercedesMastrodima, SofiaTan, Min YiShearing, SiobhanPersico, NicolaJani, Jacques CPlasencia, WalterPapaioannou, GeorgeMolina, Francisca SPoon, Liona CNicolaides, Kypros H2023-01-252023-01-252018-03-02http://hdl.handle.net/10668/12207Preeclampsia is a major pregnancy complication with adverse short- and long-term implications for both the mother and baby. Screening for preeclampsia at 11-13 weeks' gestation by a combination of maternal demographic characteristics and medical history with measurements of biomarkers can identify about 75% of women who develop preterm preeclampsia with delivery at We sought to examine the effect of prophylactic use of aspirin during pregnancy in women at high risk of preeclampsia on length of stay in the neonatal intensive care unit. This was a secondary analysis of data from the Aspirin for Evidence-Based Preeclampsia Prevention trial to assess evidence of differences in the effect of aspirin on length of stay in neonatal intensive care. Bootstrapping was used for the comparison of mean length of stay between the aspirin and placebo groups. Logistic regression was used to assess treatment effects on stay in the neonatal intensive care unit. In the trial there were 1620 participants and 1571 neonates were liveborn. The total length of stay in neonatal intensive care was substantially longer in the placebo than aspirin group (1696 vs 531 days). This is a reflection of significantly shorter mean lengths of stay in babies admitted to the neonatal intensive care unit from the aspirin than the placebo group (11.1 vs 31.4 days), a reduction of 20.3 days (95% confidence interval, 7.0-38.6; P = .008). Neonatal intensive care of babies born at In pregnancies at high risk of preeclampsia administration of aspirin reduces the length of stay in the neonatal intensive care unit by about 70%. This reduction could essentially be attributed to a decrease in the rate of births atenCombined Multimarker Screening and Randomized Patient Treatment with Aspirin for Evidence-Based Preeclampsia Prevention trialaspirinfirst-trimester screeninghealth economicsneonatal intensive carepreeclampsiaAdultAspirinEvidence-Based MedicineFemaleHumansInfant, NewbornInfant, PrematureIntensive Care Units, NeonatalLength of StayLogistic ModelsMaleOdds RatioPlatelet Aggregation InhibitorsPre-EclampsiaPregnancyresearch article29505771open access10.1016/j.ajog.2018.02.0141097-6868http://www.ajog.org/article/S000293781830173X/pdf